Purpose Intravenous vinflunine 320 mg/m 2 every 3 weeks plus best supportive care
resulted in better overall survival in comparison with best supportive care alone for eligible …

Background: The efficacy of Vinflunine, after failure of platinum-based chemotherapy in
patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract, TCCU …

Accounting for 14,000 deaths in the USA last year, research informs us that advanced
bladder cancer is a lethal disease with a median survival that has remained a little over 1 …

Relapsed urothelial cancer represents an unmet medical need. Vinflunine is a third-
generation antimicrotubuline inhibitor and is currently the only approved drug for second …

Background Vinflunine is recommended in the European guideline for the treatment of
advanced or metastatic urothelial cell carcinoma (UCC) after failure of platinum-based …

Background To retrospectively assess the efficacy and safety of Vinflunine (VFL) under
routine conditions and identify overall survival (OS) prognostic factors. Methods Twenty …

Background Patients with transitional cell carcinoma of the urothelial tract (TCCU) who fail
initial platinum-based chemotherapy for advanced disease represent a challenge in daily …

Purpose Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional
cell carcinoma of urothelial tract (TCCU). We conducted a randomized phase III study of VFL …

Background: A systematic review and meta-analysis of the use of systemic vinflunine (VIN)
in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on …

There is no standard of care in the UK or Ireland for second-line chemotherapy for patients
with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients …